EHS
EHS

STAT Plus: Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

Galectin Therapeutics (GALT) says new clinical trial data disclosed Thursday suggest its experimental cancer drug improves the efficacy of Merck’s blockbuster immunotherapy therapy Keytruda when the two drugs are used together to treat patients with advanced melanoma.

No, the new Galectin data — what little there are — show no such thing. It’s more reasonable to conclude these new data show Galectin’s drug to be a placebo.

Continue to STAT Plus to read the full story…

Source link

EHS
Back to top button